医药合约销售外包市场－全球产业规模、份额、趋势、机会及预测（按服务、治疗领域、地区及竞争格局划分，2021-2031年）

全球医药外包市场预计将从 2025 年的 76 亿美元成长到 2031 年的 106.3 亿美元，复合年增长率为 5.75%。

在这个领域，包括招募、培养和管理销售团队在内的销售职能外包给第三方供应商，由他们负责向医疗保健专业人员推广药品。该市场的主要驱动因素是製造商需要将固定商业成本转化为可变成本，以及在产品上市和专利到期等关键节点快速扩充性的需求。此外，外包使这些公司能够将资金集中投入其核心竞争优势：创新。根据欧洲製药工业协会联合会 (EFPIA) 的报告，2023 年欧洲以研发为基础的製药业预计将在研发方面投入 500 亿欧元，这凸显了优化商业支出的财务压力。

儘管存在这些成长要素，但由于不同司法管辖区严格的监管合规要求，市场仍面临许多挑战。合约销售组织必须遵守复杂的法律体制涵盖资料隐私和推广伦理，即使是轻微的违规行为也可能给製药赞助商带来严重的声誉损害和经济处罚。因此，儘管外包的策略优势显而易见，但与严格遵守各项国际法规相关的营运风险仍是市场扩张的一大挑战。

市场驱动因素

商业成本模式从固定成本转向变动成本的转变是全球医药合约销售外包市场的关键驱动因素。面对专利到期和研发（R&D）巨额资金需求，製药公司迫切需要优化损益表，他们发现维持一支传统的、庞大的、永久性的内部销售团队在财务上是不可持续的。外包使製造商能够将这些固定的人员成本转化为灵活的变动成本，从而能够快速扩展销售团队以满足产品生命週期的需求。 Fierce Biotech 2025 年 1 月的报告清楚地阐述了这种策略重组，该报告指出，2024 年大型製药企业报告的裁员轮次数量同比增长了 281%。这标誌着整个产业正在转向更精简的内部结构和外部伙伴关係。

同时，随着越来越多的公司寻求能够创建混合互动环境的供应商，先进的数位化和全通路销售技术的整合正在重塑市场格局。现代销售策略需要将线上和线下互动无缝融合，才能有效触及医疗保健专业人员 (HCP)，而他们对联繫的选择也越来越挑剔。合约销售组织 (CSO) 在提供这种复杂模式所需的数位基础设施和技术负责人方面至关重要。根据 Veeva Systems 于 2025 年 5 月发布的《Veeva Pulse Field Trends Report》，到 2024 年，美国 HCP 的就诊率将下降至 45%，这凸显了 CSO 提供的数位化连结互动策略的重要性。这种需求也反映在财务表现上。例如，IQVIA Holdings 截至 2025 年 2 月的年度报告显示，其合约销售和医疗解决方案部门预计 2024 年的收入将达到 7.18 亿美元，这为其在业务外包能力方面的大量投资提供了支持。

市场挑战

不同司法管辖区严格的监管合规要求对全球医药合约销售外包市场的扩张构成重大障碍。这种复杂性直接阻碍了市场成长，抵消了外包的关键优势：速度和灵活性。当合约销售机构 (CSO) 必须应对围绕资料隐私和推广伦理的复杂框架时，销售团队的部署会被显着延迟。因此，CSO 被迫将大量资源从实际销售活动转移到法律咨询和合规培训，这增加了营运成本，并减少了通常为医药赞助商带来的财务收益。

这种日益严格的监管环境迫使企业采取防御性营运策略，减缓了它们掌握新机会的能力。例如，处方药行为准则管理局 (PMCPA) 报告称，2024 年共收到 264 起关于潜在违反行业准则的申诉。如此巨大的监管挑战要求企业维持复杂的内部控制结构以降低风险。管理这些持续的合规义务所需的资源彙整限制了供应商快速扩张业务的能力，最终阻碍了市场加速成长的潜力。

市场趋势

全球医药合约销售外包市场正经历着向专注于肿瘤和罕见疾病领域的专业团队的显着转变。随着药物研发管线从基层医疗转向复杂的高价值治疗方法，对普通销售负责人的需求正被能够解读复杂临床数据和健保报销环境的高素质专家所取代。製药公司正利用合约销售组织（CSO）快速部署这些专业领域的专家，而无需承担设立永久性专业部门所带来的长期营运成本。这一趋势的驱动力在于上市产品的复杂性日益增加。根据美国食品药物管理局（FDA）于2025年1月发布的《2024年新药认证年度报告》，2024年核准的新药中，52%将用于治疗罕见疾病或孤儿药，因此，由专业合约销售组织提供的科学专业知识和商业性支持至关重要。

同时，医药学术专员(MSL) 和医学事务外包业务的日益普及正在改变医疗服务提供者的格局。医疗专业人员越来越需要比传统推广互动更深入的科学交流，这迫使企业将商业性销售和医学教育分开，以维护信誉和市场准入。首席科学官 (CSO) 正在积极应对这项挑战，他们赋予外包医学事务团队在产品商业性前与关键意见领袖 (KOL) 互动的能力。这种早期科学互动对于商业性成功至关重要。根据 Veeva Systems 于 2025 年 5 月发布的《Veeva Pulse 现场趋势报告》，上市前现场医学教育可使产品上市后前六个月的治疗采纳率提高 50%，这进一步凸显了外包医学团队作为确保市场渗透战略要素的重要性。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球医药合约销售外包市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按服务类型（面对面推广（销售团队、重点客户管理、职缺管理）、非面对面推广（电话推销、互动式电子推销、客户服务、医药学术专员、病人参与服务等））
  • 依治疗领域（循环系统疾病、肿瘤、代谢性疾病、神经系统疾病、整形外科疾病、感染疾病、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美医药合约销售外包市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲医药合约销售外包市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区医药合约销售外包市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲医药合约销售外包市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲医药合约销售外包市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球医药合约销售外包市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Ashfield（UDG Healthcare plc）
• inVentiv Health, Inc.（Syneos Health）
• Granard Pharmaceutical Sales & Marketing
• Vanguard Pharma, Inc.
• GTS Solution
• QFR Solutions
• Pharmaforce Ireland Ltd.
• Sales Focus, Inc.
• Amplity Health
• PharmaLex GmbH

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Pharmaceutical Contract Sales Outsourcing Market is projected to expand from USD 7.60 Billion in 2025 to USD 10.63 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 5.75%. This sector involves the delegation of sales functions-including the recruitment, training, and management of sales teams-to third-party providers responsible for promoting medicinal products to healthcare professionals. The market is primarily driven by the necessity for manufacturers to transform fixed commercial costs into variable expenses and the requirement for rapid scalability during critical events such as product launches or patent expirations. Furthermore, outsourcing allows these companies to channel capital toward their core competency of innovation, a priority evidenced by the European Federation of Pharmaceutical Industries and Associations' report that the research-based pharmaceutical industry invested an estimated €50,000 million in R&D in Europe in 2023, highlighting the financial pressure to optimize commercial expenditures.

Despite these growth drivers, the market faces significant impediments due to the rigorous demand for regulatory compliance across diverse jurisdictions. Contract sales organizations are required to navigate complex legal frameworks governing data privacy and promotional ethics, where even minor infractions can result in severe reputational damage and financial penalties for the pharmaceutical sponsor. Consequently, while the strategic benefits of outsourcing are clear, the operational risks associated with maintaining strict adherence to varying international regulations remain a substantial challenge for market expansion.

Market Driver

The shift from fixed to variable commercial cost models serves as a primary catalyst for the Global Pharmaceutical Contract Sales Outsourcing Market. Faced with intensifying pressure to optimize Profit and Loss (P&L) statements amid patent cliffs and high capital requirements for R&D, pharmaceutical companies are finding the traditional maintenance of large, permanent internal sales forces financially unsustainable. Outsourcing enables manufacturers to convert these fixed personnel liabilities into flexible variable expenses, allowing for the rapid scaling of sales teams in alignment with product lifecycle needs. This strategic restructuring is highlighted by a January 2025 report from Fierce Biotech, which noted that the number of layoff rounds reported by large pharmaceutical companies surged by 281% in 2024 compared to the prior year, indicating a decisive industry-wide move toward leaner internal structures and external partnerships.

Simultaneously, the market is being reshaped by the integration of advanced digital and omnichannel sales technologies, as companies seek providers capable of navigating a hybrid engagement landscape. Modern sales strategies necessitate a seamless combination of in-person and virtual interactions to effectively reach healthcare professionals (HCPs) who are becoming increasingly selective regarding access. Contract sales organizations are essential in supplying the digital infrastructure and tech-savvy representatives required for these complex models. According to the 'Veeva Pulse Field Trends Report' by Veeva Systems in May 2025, HCP access in the U.S. fell to 45% in 2024, emphasizing the critical need for the digitally connected engagement strategies offered by CSOs. This demand is reflected in financial results, such as IQVIA Holdings Inc.'s February 2025 Annual Report, which revealed that their Contract Sales & Medical Solutions segment generated $718 million in revenue for 2024, underscoring the significant investment in outsourced capabilities.

Market Challenge

The rigorous demand for regulatory compliance across varying jurisdictions acts as a formidable barrier to the expansion of the Global Pharmaceutical Contract Sales Outsourcing Market. This complexity directly hinders growth by neutralizing the primary benefits of outsourcing, specifically speed and agility. When Contract Sales Organizations (CSOs) are required to navigate intricate frameworks regarding data privacy and promotional ethics, the deployment of sales teams is significantly delayed. Consequently, CSOs must divert substantial resources from actual sales execution toward legal counsel and compliance training, which increases operational costs and diminishes the financial advantages typically afforded to pharmaceutical sponsors.

This environment of heightened scrutiny forces organizations to adopt a defensive operational posture, thereby slowing their ability to capitalize on new opportunities. For instance, the Prescription Medicines Code of Practice Authority (PMCPA) reported receiving 264 complaints regarding potential breaches of industry codes in 2024. Such a high volume of regulatory challenges necessitates that CSOs maintain elaborate internal governance structures to mitigate risk. The resource intensity required to manage these ongoing compliance obligations limits the capacity of providers to scale operations rapidly, ultimately stalling the market's potential for accelerated growth.

Market Trends

The Global Pharmaceutical Contract Sales Outsourcing Market is increasingly characterized by a shift toward specialized teams focused on oncology and rare diseases. As pharmaceutical pipelines move away from primary care blockbusters in favor of complex, high-value therapies, the demand for generalist sales representatives is being replaced by a need for highly trained professionals capable of discussing intricate clinical data and reimbursement landscapes. Pharmaceutical sponsors are leveraging Contract Sales Organizations (CSOs) to rapidly deploy these niche experts without the long-term overhead associated with permanent specialized units. This trend is driven by the rising volume of complex market entrants; according to the '2024 New Drug Therapy Approvals Annual Report' by the U.S. Food and Drug Administration in January 2025, 52% of novel drugs approved in 2024 were for rare diseases or orphan indications, necessitating the scientifically literate commercial support that specialized CSOs provide.

Concurrently, the expansion of Medical Science Liaison (MSL) and Medical Affairs outsourcing is reshaping the provider landscape. Healthcare professionals are increasingly demanding deeper scientific exchange rather than traditional promotional interactions, compelling companies to separate commercial sales from medical education to maintain credibility and access. CSOs are responding by offering outsourced Medical Affairs teams capable of engaging Key Opinion Leaders (KOLs) well ahead of a product's commercial release. This early scientific engagement is vital for commercial success; the 'Veeva Pulse Field Trends Report' from Veeva Systems in May 2025 found that pre-launch field medical education improved treatment adoption by 50% during the first six months of a launch, driving a strategic reliance on outsourced medical teams to secure market uptake.

Key Market Players

• Ashfield (UDG Healthcare plc)
• inVentiv Health, Inc. (Syneos Health)
• Granard Pharmaceutical Sales & Marketing
• Vanguard Pharma, Inc.
• GTS Solution
• QFR Solutions
• Pharmaforce Ireland Ltd.
• Sales Focus, Inc.
• Amplity Health
• PharmaLex GmbH

Report Scope

In this report, the Global Pharmaceutical Contract Sales Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Contract Sales Outsourcing Market, By Service

• Personal Promotion (Promotional Sales Team, Key Account Management, Vacancy Management)
• Non-personal Promotion (Tele-detailing, Interactive E-detailing, Customer Service, Medical Science Liaisons, Patient Engagement Services, Others)

Pharmaceutical Contract Sales Outsourcing Market, By Therapeutic Area

• Cardiovascular Disorders
• Oncology
• Metabolic Disorders
• Neurology
• Orthopedic Diseases
• Infectious Diseases
• Others

Pharmaceutical Contract Sales Outsourcing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Contract Sales Outsourcing Market.

Available Customizations:

Global Pharmaceutical Contract Sales Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Contract Sales Outsourcing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Personal Promotion (Promotional Sales Team, Key Account Management, Vacancy Management), Non-personal Promotion (Tele-detailing, Interactive E-detailing, Customer Service, Medical Science Liaisons, Patient Engagement Services, Others))
  • 5.2.2. By Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Pharmaceutical Contract Sales Outsourcing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Therapeutic Area
  • 6.3.2. Canada Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Therapeutic Area
  • 6.3.3. Mexico Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Therapeutic Area

7. Europe Pharmaceutical Contract Sales Outsourcing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Therapeutic Area
  • 7.3.2. France Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Therapeutic Area
  • 7.3.3. United Kingdom Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Therapeutic Area
  • 7.3.4. Italy Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Therapeutic Area
  • 7.3.5. Spain Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Pharmaceutical Contract Sales Outsourcing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Therapeutic Area
  • 8.3.2. India Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Therapeutic Area
  • 8.3.3. Japan Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Therapeutic Area
  • 8.3.4. South Korea Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Therapeutic Area
  • 8.3.5. Australia Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Therapeutic Area

9. Middle East & Africa Pharmaceutical Contract Sales Outsourcing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Therapeutic Area
  • 9.3.2. UAE Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Therapeutic Area
  • 9.3.3. South Africa Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Therapeutic Area

10. South America Pharmaceutical Contract Sales Outsourcing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Therapeutic Area
  • 10.3.2. Colombia Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Therapeutic Area
  • 10.3.3. Argentina Pharmaceutical Contract Sales Outsourcing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pharmaceutical Contract Sales Outsourcing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Ashfield (UDG Healthcare plc)
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. inVentiv Health, Inc. (Syneos Health)
• 15.3. Granard Pharmaceutical Sales & Marketing
• 15.4. Vanguard Pharma, Inc.
• 15.5. GTS Solution
• 15.6. QFR Solutions
• 15.7. Pharmaforce Ireland Ltd.
• 15.8. Sales Focus, Inc.
• 15.9. Amplity Health
• 15.10. PharmaLex GmbH

16. Strategic Recommendations

17. About Us & Disclaimer